Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Advancements in oncolytic virus therapy: a new horizon for ovarian cancer

Abstract

Ovarian cancer remains the most lethal gynecological malignancy, and the limited durability of standard treatments has motivated the development of new therapeutic strategies. Oncolytic viruses selectively replicate within and lyse tumor cells, releasing tumor antigens and inflammatory signals that can convert an immunosuppressive tumor microenvironment into an immune-inflamed state. This review evaluates the principal platforms used in ovarian cancer, including adenovirus, reovirus, measles virus, vaccinia virus, herpes simplex virus, and vesicular stomatitis virus. We compare engineering approaches that enhance tumor-selective replication, cellular entry, transgene delivery, and local immune activation, and discuss strategies to overcome neutralizing antibodies, restricted intratumoral spread, off-target toxicity, and tumor heterogeneity. Particular emphasis is placed on cytokine- or bispecific T-cell engager-armed viruses and their combination with chemotherapy, immune checkpoint blockade, and cellular immunotherapy. Early-phase studies support the feasibility of intraperitoneal delivery, whereas a single-arm phase 2 study of Olvi-Vec followed by platinum-based chemotherapy reported encouraging results, and a randomized phase 3 trial is ongoing. No oncolytic viruses have been approved for ovarian cancer; however, current evidence supports biomarker-guided and rationally sequenced clinical development.

Related

  1. Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
    Qingqing Wang, Qingqing Wang, Qingqing Wang +31
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineDOAJFrontiersCrossref
  2. The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery
    Rawan H. Alsharedeh, Alaa A. A. Aljabali, Mohammad A. Obeid +6
    RSC AdvancesPeer-reviewedCC BY-NC 3.0Full textGenetics & genomicsPMCEurope PMC
  3. Receptor-guided engineering of oncolytic vaccinia creates a synthetic support niche for off-the-shelf NK cell therapy
    R. Rezaei, Z. Gan, N. Akeem Akilimali +12
    bioRxivPreprintAll rights reservedFull textSystems & synthetic biologybioRxiv
  4. Tumor Biology, Genetic Risk, and Systemic Therapy in Familial Breast Cancer: An 8-Year Experience from a German Center for Familial Breast and Ovarian Cancer.
    Maria Eleni Hatzipanagiotou, Lisa Witterauf, Mikosch Augele +10
    Breast care (Basel, Switzerland)Peer-reviewedCC BYFull textGenetics & genomicsEurope PMC
  5. The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy
    Zhiqi Liao, Linghui Wang, Ziyan Zhang +15
    Journal of Hematology & OncologyPeer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyPMC
BibTeX
@article{wang2026advancements,
  title = {{Advancements in oncolytic virus therapy: a new horizon for ovarian cancer}},
  author = {Qiuman Wang and Yu Sun and Ruxin Liu and Beihua Kong and Jie Li and Kun Song and Hui Zhang and Cunzhong Yuan},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.2026491},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2026491},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Advancements in oncolytic virus therapy: a new horizon for ovarian cancer
AU  - Qiuman Wang
AU  - Yu Sun
AU  - Ruxin Liu
AU  - Beihua Kong
AU  - Jie Li
AU  - Kun Song
AU  - Hui Zhang
AU  - Cunzhong Yuan
PY  - 2026
DA  - 2026/11/10
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.2026491
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2026491
AB  - Ovarian cancer remains the most lethal gynecological malignancy, and the limited durability of standard treatments has motivated the development of new therapeutic strategies. Oncolytic viruses selectively replicate within and lyse tumor cells, releasing tumor antigens and inflammatory signals that can convert an immunosuppressive tumor microenvironment into an immune-inflamed state. This review evaluates the principal platforms used in ovarian cancer, including adenovirus, reovirus, measles virus, vaccinia virus, herpes simplex virus, and vesicular stomatitis virus. We compare engineering approaches that enhance tumor-selective replication, cellular entry, transgene delivery, and local immune activation, and discuss strategies to overcome neutralizing antibodies, restricted intratumoral spread, off-target toxicity, and tumor heterogeneity. Particular emphasis is placed on cytokine- or bispecific T-cell engager-armed viruses and their combination with chemotherapy, immune checkpoint blockade, and cellular immunotherapy. Early-phase studies support the feasibility of intraperitoneal delivery, whereas a single-arm phase 2 study of Olvi-Vec followed by platinum-based chemotherapy reported encouraging results, and a randomized phase 3 trial is ongoing. No oncolytic viruses have been approved for ovarian cancer; however, current evidence supports biomarker-guided and rationally sequenced clinical development.
SN  - 1664-3224
ER  -